← Back to headlines
Sanofi Unveils Phase 3 Amlitelimab Data for Atopic Dermatitis
Sanofi has announced late-breaking phase 3 data for its drug amlitelimab, targeting atopic dermatitis, a significant development in the treatment of the skin condition.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
AI Drone Project Launched to Detect Banana Disease in Davao Region
just now
NASA's Artemis II Mission Preparations Intensify, Gaining Broader Attention
28m ago
Namibia Critical Metals Amends Lofdal JV with JOGMEC, Secures Feasibility Funding
43m ago
Anthropic's 'Mythos' AI Model Deemed Too Dangerous for Release, Raising Cyberattack Concerns
43m ago